G
Guillermo Lopez-Vivanco
Researcher at University of Zaragoza
Publications - 101
Citations - 9219
Guillermo Lopez-Vivanco is an academic researcher from University of Zaragoza. The author has contributed to research in topics: Lung cancer & Docetaxel. The author has an hindex of 21, co-authored 95 publications receiving 8397 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell,Teresa Moran,Cristina Queralt,Rut Porta,Felipe Cardenal,Carlos Camps,Margarita Majem,Guillermo Lopez-Vivanco,Dolores Isla,Mariano Provencio,A. Insa,Bartomeu Massuti,José Luis González-Larriba,Luis Paz-Ares,Isabel Bover,Rosario García-Campelo,Miguel Angel Moreno,Silvia Catot,Christian Rolfo,Noemi Reguart,Ramon Palmero,Jose Miguel Sanchez,Roman Bastus,Clara Mayo,Jordi Bertran-Alamillo,Miguel Angel Molina,Jose Javier Sanchez,Miquel Taron +27 more
TL;DR: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment, and the association between the mutations and the outcome of erlotinib treatment is analyzed.
Journal ArticleDOI
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
M. Cobo,Dolores Isla,Bartomeu Massuti,Ana Montes,Jose Miguel Sanchez,Mariano Provencio,Nuria Viñolas,Luis Paz-Ares,Guillermo Lopez-Vivanco,Miguel Angel Muñoz,Enriqueta Felip,Vicente Alberola,Carlos Camps,Manuel Domine,Jose Javier Sanchez,Maria Sanchez-Ronco,K. D. Danenberg,Miquel Taron,David R. Gandara,Rafael Rosell +19 more
TL;DR: Assessment of ERCC1 mRNA expression in patient tumor tissue is feasible in the clinical setting and predicts response to docetaxel and cisplatin, and a multibiomarker profile predictive of patient outcome is refined.
Journal ArticleDOI
Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer
Dolores Isla,Carme Sarries,Rafael Rosell,Guillermo Alonso,Manuel Domine,Miquel Taron,Guillermo Lopez-Vivanco,Carlos Camps,M. Botia,L. Nuñez,Maria Sanchez-Ronco,Jose Javier Sanchez,Marta López-Brea,Isidoro Barneto,A. Paredes,B. Medina,Angel Artal,Pilar Lianes +17 more
TL;DR: ERCC1 SNP assessment could be an important component of tailored chemotherapy trials and patients homozygous for the ERCC1 118 C allele demonstrated a significantly better survival.
Journal ArticleDOI
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Vicente Alberola,Carlos Camps,Mariano Provencio,Dolores Isla,Rafael Rosell,C. Vadell,Isabel Bover,Ana Ruiz-Casado,P. Azagra,Ulpiano Jimenez,Jose-Luis Gonzalez-Larriba,Pilar Diz,Felipe Cardenal,Angel Artal,Alfredo Carrato,Serafin Morales,José Jurado Sánchez,R. de las Peñas,Enriqueta Felip,Guillermo Lopez-Vivanco +19 more
TL;DR: CG remains a standard regimen for first-line treatment of advanced NSCLC on the basis of results, and no differences in median survival or time to progression were observed.